FDA Initiates Class II Recall for Akron Pharma's OneLAX Docusate Sodium Liquid Due to CGMP Deviations
Akron Pharma, Inc. has initiated a nationwide Class II recall (D-0025-2025) for 10,845 bottles of OneLAX Docusate Sodium Liquid due to Current Good Manufacturing Practice (CGMP) deviations. This event necessitates immediate review by procurement, supply chain, and regulatory teams to assess inventory, mitigate disruption, and ensure compliance with FDA standards for this critical over-the-counter laxative.
FDA Initiates Class II Recall for Akron Pharma's OneLAX Docusate Sodium Liquid
Akron Pharma, Inc., based in Fairfield, NJ, has initiated a voluntary, firm-initiated Class II recall, identified as D-0025-2025, for its OneLAX Docusate Sodium Liquid. This significant regulatory action stems from identified Current Good Manufacturing Practice (CGMP) deviations, impacting a widely used over-the-counter stool softener laxative. For procurement directors, this event signals an urgent requirement to verify existing inventory levels and critically assess sourcing strategies for docusate sodium, a key active pharmaceutical ingredient in many formulations. Regulatory affairs teams must recognize the FDA’s Class II classification, which indicates that exposure to the product could lead to temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification, coupled with the recall’s initiation on October 15, 2024, and subsequent FDA classification on October 24, 2024, underscores the rapid response expected from pharmaceutical manufacturers regarding compliance issues. Business development executives should evaluate the competitive landscape for similar laxative products, as market disruption from such recalls can create opportunities for compliant manufacturers to expand their market share.
Specifics of CGMP Deviations and Affected Product Batches
The fundamental issue driving this recall is attributed to Current Good Manufacturing Practice (CGMP) deviations. While the precise nature of these deviations remains unspecified in the public recall notice, the FDA's Class II designation implies that these manufacturing deficiencies are significant enough to potentially compromise the product's quality, safety, or efficacy. The affected product is specifically OneLAX Docusate Sodium Liquid, formulated at 50 mg/5 mL, and distributed in 16 FL OZ (473 mL) bottles. This product is manufactured for Akron Pharma, Inc., located at 373 US Highway 46 Ste 117, Fairfield, NJ 07004, and is identified by the National Drug Code (NDC) 71399-0039-06. A total of 10,845 bottles are subject to this recall, encompassing three distinct production lots: ODS230001A and ODS230002A, both with an expiration date of October 2025, and lot ODS230003A, which expires in November 2025. Supply chain VPs must ensure immediate quarantine and return of these specific lot numbers to prevent further distribution and ensure strict adherence to the recall directive. Regulatory affairs personnel are advised to conduct internal audits to identify and address any similar CGMP vulnerabilities within their own manufacturing operations, particularly for over-the-counter pharmaceutical products.
Nationwide Distribution and Commercial Implications for Docusate Sodium Supply
The distribution pattern for Akron Pharma’s recalled OneLAX Docusate Sodium Liquid is nationwide across the United States. This extensive reach implies that pharmacies, wholesale distributors, and healthcare providers throughout the country are potentially impacted, necessitating a robust and comprehensive recall execution strategy. For procurement directors, the nationwide scope mandates an urgent and thorough review of all docusate sodium-based product inventories, irrespective of the original supplier, to identify any potential gaps or over-reliance on Akron Pharma’s supply. Although the recalled quantity of 10,845 bottles might appear moderate within the vast pharmaceutical market, any disruption in the supply of a commonly used over-the-counter medication like docusate sodium can lead to localized shortages and affect patient access. Supply chain VPs must critically assess their existing supplier diversification strategies for docusate sodium and related laxative products. The absence of specific alternative suppliers in the current intelligence highlights the imperative for proactive supplier qualification and maintaining a resilient multi-source strategy for all critical raw materials and finished pharmaceutical goods. Business development executives should closely monitor market demand shifts and competitor responses, as this event could drive increased demand for alternative docusate sodium products or other laxative formulations from compliant manufacturers.
Broader Regulatory Context and Industry Vigilance
This Class II recall initiated by Akron Pharma, Inc. is set against a backdrop of intensified regulatory scrutiny by the FDA across the global chemical and life sciences industries. Recent parallel events underscore this heightened vigilance, including Essential Wellness Pharma’s Class II recall of Progesterone Injection due to failures in sterility assurance, and the FDA hearing that placed Amgen’s Tavneos market future at risk following an independent data review. These incidents, while distinct in their specific causes and affected products, collectively signal a consistent and unwavering FDA focus on manufacturing quality, product integrity, and data reliability across the pharmaceutical sector. Regulatory affairs heads must interpret these actions as a clear directive to bolster internal quality management systems, conduct rigorous risk assessments, and ensure continuous adherence to evolving Current Good Manufacturing Practice (CGMP) standards. The FDA’s proactive stance on issues ranging from fundamental manufacturing deviations to sterility concerns and data integrity means that companies cannot afford any complacency. Procurement directors and supply chain VPs should view these regulatory enforcement actions not as isolated occurrences, but as indicators of systemic risks that necessitate robust supplier auditing programs, stringent quality agreements, and a comprehensive understanding of their entire supply chain’s regulatory compliance posture to safeguard against similar market disruptions.